Trial Profile

Larotrectinib (LOXO-101, NSC788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larotrectinib (Primary) ; Larotrectinib (Primary)
Indications CNS cancer; Fibrosarcoma; Leukaemia; Sarcoma; Solid tumours
Focus Therapeutic Use

Most Recent Events

09 Dec 2024 Results presented in the Title Children's Hospital of Philadelphia Media Release.
25 Nov 2024 Planned End Date changed from 30 Sep 2025 to 20 Nov 2025.
29 Oct 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com